Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
FibroBiologics, Inc. - Common Stock
(NQ:
FBLG
)
2.560
+0.090 (+3.64%)
Streaming Delayed Price
Updated: 4:00 PM EST, Nov 27, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about FibroBiologics, Inc. - Common Stock
< Previous
1
2
Next >
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
November 19, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Pre-Market Session
November 14, 2024
Via
Benzinga
FibroBiologics Files Patent Application Covering Reduction of Blood Clots Associated with Instant Blood-Mediated Inflammatory Reaction (IBMIR) in Cell-Based Therapeutics
November 14, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Reports Third Quarter 2024 Financial Results and Provides Corporate Update
November 12, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
This NANO Nuclear Energy Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
October 30, 2024
Via
Benzinga
FibroBiologics Announces Updates for Novel Artificial Thymus Organoid Technology
October 29, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at the 2024 ThinkEquity Conference and BIO-Europe 2024
October 28, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics and Charles River Announce Collaboration to Manufacture Fibroblast Cell-based Therapies for Chronic Diseases
October 18, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Issued Patent for Fibroblast Delivery of Tumor Inhibitory Agents by the European Patent Office
October 16, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Participate in a Fireside Chat at 2024 Maxim Healthcare Virtual Summit
October 11, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at 2024 Cell & Gene Meeting on the Mesa
September 30, 2024
Chief Scientific Officer, Hamid Khoja, Ph.D., to provide update on Psoriasis and Wound Care programs
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Engages Southern Star Research as CRO in Australia
September 19, 2024
Southern Star Research will provide CRO services for FibroBiologics in Australia
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Filing of Patent Application for Generation of Three-dimensional Organoids using Fibroblast Cell-Based Technology
September 12, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 06, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
September 02, 2024
Via
Benzinga
FibroBiologics Announces Filing of Patent Application for Wound Healing Using an Adhesive Bandage with Fibroblast Cell-Based Technology
August 20, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Files 2024 Second Quarter Report
August 07, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at JonesTrading Healthcare Summit 2024
July 15, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Announces Preliminary Proof of Concept for Novel Artificial Thymus Organoid Technology
June 25, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics Set to Join Russell 2000® Index
June 13, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
June 11, 2024
Via
Benzinga
Vail Resorts Posts Downbeat Q3 Results, Joins Concrete Pumping, DocuSign And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 07, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
June 06, 2024
Via
Benzinga
FibroBiologics to Present at Extracellular Matrix Pharmacology Congress 2024
June 06, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
June 05, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
June 05, 2024
Via
Benzinga
FibroBiologics Announces 2024 Annual Meeting of Stockholders
May 15, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FBLG Stock Earnings: FibroBiologics, Inc. – Common Stock Reported Results for Q1 2024
May 15, 2024
FibroBiologics, Inc. - Common Stock just reported results for the first quarter of 2024.
Via
InvestorPlace
FibroBiologics Files 2024 First Quarter Report
May 14, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
FibroBiologics to Present at the BIO International Convention 2024
May 07, 2024
From
Fibrobiologics, Inc.
Via
GlobeNewswire
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.